FAM8A1 Inhibitors
FAM8A1 inhibitors generally operate by thwarting crucial cellular signaling pathways. Many target the EGFR signaling cascade; compounds such as Erlotinib, Gefitinib, Lapatinib, and Afatinib bind to the ATP-binding site of the EGFR tyrosine kinase, thereby reducing its activation. By doing so, these inhibitors can indirectly suppress FAM8A1 activity, as the protein functions downstream of EGFR. This method of action effectively disrupts the EGFR signaling pathway, leading to the indirect impairment of FAM8A1.
Simultaneously, FAM8A1 inhibitors may target the PI3K/AKT signaling pathway, of which FAM8A1 is a part. Inhibitors such as PI-103, LY294002, Wortmannin, and GDC-0941 are potent PI3K inhibitors that reducing the activation of the PI3K/AKT pathway, thus indirectly inhibiting FAM8A1. Additionally, AKT-specific inhibitors like MK-2206, AZD5363, Perifosine, and Triciribine operate by specifically inhibiting AKT, a key component of the PI3K/AKT pathway, indirectly leading to the functional inhibition of FAM8A1. Therefore, by disrupting these key signaling pathways, the inhibitors can indirectly suppress FAM8A1's activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an EGFR inhibitor that binds to the ATP-binding site of the EGFR tyrosine kinase, preventing its activation. FAM8A1, functioning downstream of EGFR, can be indirectly inhibited when EGFR signaling is suppressed. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib inhibits EGFR by binding to its ATP-binding site. This inhibition results in the suppression of the downstream signaling, including FAM8A1. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib inhibits both EGFR and HER2/neu tyrosine kinases, disrupting downstream signaling. This disruption can lead to the functional inhibition of FAM8A1. | ||||||
Afatinib-d4 | 850140-72-6 (unlabeled) | sc-481821 | 10 mg | $4665.00 | ||
Afatinib irreversibly inhibits EGFR, HER2, and HER4, impeding these signaling pathways, which can lead to decreased activity of FAM8A1. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $32.00 $128.00 | 3 | |
PI-103 is a PI3K inhibitor that directly inhibits the PI3K/AKT pathway, a pathway in which FAM8A1 is involved. This can result in the indirect inhibition of FAM8A1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that disrupts the PI3K/AKT pathway, indirectly inhibiting FAM8A1 through this pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor that by inhibiting the PI3K/AKT pathway can lead to the indirect functional inhibition of FAM8A1. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $184.00 $195.00 | 2 | |
GDC-0941 is a PI3K inhibitor that disrupts the PI3K/AKT pathway, leading to the indirect inhibition of FAM8A1. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $178.00 $325.00 | 67 | |
MK-2206 is an AKT inhibitor that influences the PI3K/AKT pathway, leading to an indirect inhibition of FAM8A1. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363 is an AKT inhibitor that disrupts the PI3K/AKT pathway, indirectly leading to the functional inhibition of FAM8A1. | ||||||